Baron Szilvia, Binenbaum Yoav, Maman Ronny, Fidel Victoria, Shusterman Anna, Vaisman Dmitry, Sher Osnat, Manisterski Michal, Shukrun Rachel, Rössig Claudia, Elhasid Ronit
School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel.
Front Oncol. 2025 Mar 19;15:1472716. doi: 10.3389/fonc.2025.1472716. eCollection 2025.
Osteosarcoma (OS), the most common primary bone malignancy in childhood poses a therapeutic challenge despite extensive research. Neutrophil extracellular traps (NETs) play a role in the tumor microenvironment (TME) in a variety of cancers, but their role in OS has not been characterized.
This retrospective cohort study aimed to investigate immune cell infiltration and NETs formation in patients with OS and its association with chemotherapy response and overall survival using immunofluorescence of paraffin-embedded tissue samples.
As compared to the non-malignant bone tumor Osteoblastoma, OS samples were characterized by a higher proportion of neutrophils exhibiting NETs. High NETs formation on initial diagnostic biopsies, but not Neutrophil to Lymphocyte ratio, the number of tumor-infiltrating neutrophils, CD3 T-cells or CD8 T-cells, was associated with poor response to neoadjuvant chemotherapy. The NETs burden in diagnostic biopsies was also correlated with survival: patients with high NETs burden had a mean overall survival of 53.7 months, as compared with 71.5 months for patients with low NETs. Furthermore, metastatic sites exhibited elevated NETs formation compared to primary tumors, and sera from patients with OS induced NETs release in healthy neutrophils, while sera from healthy controls did not.
These data highlight the potential role of NETs in OS's TME biology, and suggest that NETs released by tumor infiltrating neutrophils can serve as an independent prognostic factor for poor response to neoadjuvant therapy and overall survival in patients with OS. Such insights may inform the development of tailored treatment approaches in OS.
骨肉瘤(OS)是儿童期最常见的原发性骨恶性肿瘤,尽管进行了广泛研究,但仍面临治疗挑战。中性粒细胞胞外陷阱(NETs)在多种癌症的肿瘤微环境(TME)中发挥作用,但其在骨肉瘤中的作用尚未明确。
这项回顾性队列研究旨在通过对石蜡包埋组织样本进行免疫荧光分析,研究骨肉瘤患者的免疫细胞浸润和NETs形成及其与化疗反应和总生存期的关系。
与非恶性骨肿瘤成骨细胞瘤相比,骨肉瘤样本的特点是呈现NETs的中性粒细胞比例更高。初始诊断活检时NETs形成水平高,而非中性粒细胞与淋巴细胞比值、肿瘤浸润中性粒细胞数量、CD3 T细胞或CD8 T细胞数量与新辅助化疗反应不佳相关。诊断活检中的NETs负荷也与生存期相关:NETs负荷高的患者平均总生存期为53.7个月,而NETs负荷低的患者为71.5个月。此外,转移部位的NETs形成比原发性肿瘤更高,骨肉瘤患者的血清可诱导健康中性粒细胞释放NETs,而健康对照者的血清则不能。
这些数据突出了NETs在骨肉瘤TME生物学中的潜在作用,并表明肿瘤浸润中性粒细胞释放的NETs可作为骨肉瘤患者新辅助治疗反应不佳和总生存期的独立预后因素。这些见解可能为骨肉瘤个性化治疗方法的开发提供依据。